主要学术成就： 近年来围绕卵巢癌的侵袭转移机制、卵巢癌预后预测模型及卵巢癌的免疫治疗开展了一系列的研究工作。在机制研究方面，分别从肿瘤代谢、竞争性内源RNA、表观遗传调控三个方向揭示卵巢癌侵袭的新机制：活性氧通过HIF-1α/ LOX 通路促进卵巢癌进展；环状RNA hsa_circ_0078607作为内源性竞争RNA通过miR-518a-5p/Fas信号通路抑制卵巢癌细胞增殖侵袭；赖氨酸甲基转移酶SMYD3通过下调p53蛋白稳定性促进卵巢癌转移，为阐明卵巢癌侵袭转移机制提供了新的理论依据。在卵巢癌预后预测方面，发现了一系列与卵巢癌预后相关的炎症、凝血和营养指标，通过结合血清中CA125浓度建立卵巢癌个体化预后评估的三个新方法：FA评分系统，F-NLR预测模型，血小板/淋巴细胞比值评价体系，为预测卵巢癌结局提供了实用工具，指导临床实践，助力精准医疗。在卵巢癌治疗方面：一是采用细胞膜包裹纳米颗粒的生物工程学技术，制备了卵巢癌特异性的仿生纳米疫苗mini DC，论证了该疫苗在抑制卵巢癌细胞生长及转移上的有效性，有效克服了传统树突状细胞疫苗活性差、效率低的缺陷，为卵巢癌的精准治疗提供了新思路，具有潜在的临床应用价值；二是设计了新一代靶向PARP1蛋白的PROTAC降解剂，抑制PARP1酶活的同时减少了DNA捕获效应，并在BRCA缺陷的肿瘤中展现出安全且有效的抗肿瘤疗效。主持科技部重点专项、国家自然科学基金面上项目等各类课题20余项，总经费2000余万元，以第一作者或通讯作者在Advenced Science、Cell Death & Diseases等国内外核心期刊发表专业论著100余篇，申请国家专利十余项，已获授权发明专利1项、实用新型专利5项、软著4项。现已培养博士、硕士研究生20余名，在读博士、硕士研究生13名。多名学生获得博士研究生国家奖学金、上海市优秀毕业生、上海交通大学优秀毕业生、同济大学优秀学生等荣誉称号，4名毕业生获得上海市“扬帆计划”人才项目资助。以第三完成人参与完成的教学项目《以育人为本、以提升临床胜任力为导向的妇产科学课程改革与实践》，获得上海交通大学2020年度教学成果二等奖。 科技奖项： 2022年，《转移性卵巢癌关键诊疗技术和策略的创新及机制研究》，上海医学科技奖一等奖，第一完成人 2023年，《卵巢癌预防及全程慢病化管理系列科普推广》， 上海科普教育创新奖科普贡献奖（个人）一等奖 2025年，《卵巢癌关键诊疗策略和技术的创新及应用》，中华医学科技奖二等奖，第一完成人 重要论文： 1. Dual-channel and Dual-mode Imaging System for High-performance Cancer Surgery Using Fluorescence Quantum Yield Enhanced Aggregation-induced Emission Luminogens. Laser Photonics Rev 19, no. 23 (2025): e01232 2. Identification of a tertiary lymphoid structure (TLS)-related signature for ovarian cancer prognosis suggests a potential role of STAT5A in TLS maturation. Genes Dis. 2025 Jan 4;12(5):101514. 3. Profiling of RUVBL2-Induced Transcriptome Alterations Highlights a Critical Role for Chromatin Remodeling in Ovarian Cancer. Biofactors. 2025 Jul-Aug;51(4):e70041. 4.  Targeting CDK9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian Cancer. Phytother Res. 2025 Aug;39(8):3648-3663. 5.  The value of MRI in differentiating ovarian clear cell carcinoma from other adnexal masses with O-RADS MRI scores of 4-5. Insights Imaging. 2025 Jan 29;16(1):22. 6.  Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis. BMC Cancer. 2025 Feb 26;25(1):355. 7.  Artificial intelligence algorithm for preoperative prediction of FIGO stage in ovarian cancer based on clinical features integrated 18F-FDG PET/CT metabolic and radiomics features. J Cancer Res Clin Oncol. 2025 Feb 20;151(2):87. 9.  Pixantrone as a novel MCM2 inhibitor for ovarian cancer treatment. Eur J Pharmacol. 2024 Sep 15;979:176835. 10.  Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database. J Cancer. 2024 Jan 1;15(2):473-483. 11.  A Neutrophil Extracellular Traps-Related Signature Predicts Clinical Outcomes and Identifies Immune Landscape in Ovarian Cancer. J Cell Mol Med. 2024 Dec;28(24):e70302. 12.  Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader. Cell Death Dis. 2024 Dec 18;15(12):898. 13. Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer. Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189221. 14. PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells. Cell Death Dis. 2024 Aug 22;15(8):610. 15.  Boosted photo-immunotherapy via near-infrared light excited phototherapy in tumor sites and photo-activation in sentinel lymph nodes. Nanoscale Adv. 2024 Mar 5;6(8):2075-2087. 16.  Identification of the prognostic value of LACTB2 and its correlation with immune infiltrates in ovarian cancer by integrated bioinformatics analyses. Eur J Med Res. 2024 Mar 12;29(1):166. 17.  Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer. BMC Cancer. 2024 Feb 26;24(1):267. 18.  Pre-fusion motion state determines the heterogeneity of membrane fusion dynamics for large dense-core vesicles. Acta Physiol (Oxf). 2024 Apr;240(4):e14115. 19.  Multitask prediction models for serous ovarian cancer by preoperative CT image assessments based on radiomics. Front Med (Lausanne). 2024 Feb 6;11:1334062. 20.  Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer. Cancer Cell Int. 2024 Feb 3;24(1):53. 21.  Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9. Biomolecules. 2023 Nov 30;13(12):1724. 22.  CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1. Cell Oncol (Dordr). 2024 Jun;47(3):897-915. 23.  Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancer. Cancer Cell Int. 2023 Oct 6;23(1):232. 24. Polystyrene nanoparticle exposure accelerates ovarian cancer development in mice by altering the tumor microenvironment. Sci Total Environ. 2024 Jan 1;906:167592. 25. Endoplasmic Reticulum Stress-Related Ten-Biomarker Risk Classifier for Survival Evaluation in Epithelial Ovarian Cancer and TRPM2: A Potential Therapeutic Target of Ovarian Cancer. Int J Mol Sci. 2023 Sep 12;24(18):14010. 26.  A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer. J Ovarian Res. 2023 Sep 20;16(1):196. 27.  A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer. J Ovarian Res. 2023 Apr 29;16(1):86. 28.  Construction and validation of a novel ferroptosis-related signature for evaluating prognosis and immune microenvironment in ovarian cancer. Front Genet. 2023 Jan 5;13:1094474. 29.  Exploring prognostic indicators in the pathological images of ovarian cancer based on a deep survival network. Front Genet. 2023 Jan 4;13:1069673. 30.  Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res. 2023 Jan 7;16(1):6.